Four consecutive earnings beats averaging approximately 11% above consensus and free cash flow converting at roughly 3x reported net income demonstrate operational and cash generation strength; however, the stock has moved above its near-term resistance target with an unfavorable risk/reward setup and overbought momentum readings at an RSI of 83, arguing for patience rather than action at current prices.
Thesis pillars
- Sole Supplier Concentration Risk↓Deteriorating
- Consistent Earnings Beat Streak→Stable
- Exceptional Free Cash Generation→Stable
- +1 more pillar — see the Why tab for full reasoning
Cardinal Health, Inc. (CAH) Stock Analysis
Catalyst-Driven edge
Healthcare · Medical Distribution
Sell if holding. Engine safety override at $238.08: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality.
Cardinal Health distributes pharmaceuticals and medical products and operates specialty and at-Home Solutions businesses through its Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, and Specialty segments. CVS Health, its largest customer,... Read more
Sell if holding. Engine safety override at $238.08: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 23d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Cardinal Health, Inc.
About Cardinal Health, Inc.
Cardinal Health's largest customer, CVS Health, accounted for 30% of fiscal 2025 revenue, with its five largest customers together representing 43%. Sales through its two largest group purchasing organizations, Vizient and Premier, added another 27% of revenue. The company employed approximately 57,700 people globally as of June 30, 2025, and completed five acquisitions between March 2024 and May 2025, including GI Alliance for $2.8 billion and Advanced Diabetes Supply Group for $1.1 billion.
Cardinal Health's Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals and over-the-counter products to retail pharmacies, hospitals, and other providers, earning margin from its generic pharmaceutical program, distribution services agreements with branded manufacturers (typically a percentage of wholesale acquisition cost), and manufacturer cash discounts; its Red Oak Sourcing joint venture with CVS Health negotiates generic drug supply contracts through June 2029. The Specialty businesses distribute oncology, rheumatology, urology, and nephrology products and human-derived plasma, plus consulting and MSO support for physician practices following recent acquisitions of GI Alliance, Integrated Oncology Network, and Specialty Networks. The GMPD segment manufactures Cardinal Health-branded gloves, wound care, incontinence, and surgical products alongside distributing third-party national-brand medical products, while smaller segments cover nuclear pharmacy radiopharmaceuticals (Xofigo, Lymphoseek), at-Home Solutions medical supply delivery (including the newly acquired ADS diabetes supply business), and OptiFreight shipping logistics. Competitors include McKesson, Cencora, Medline, and Owens & Minor.
Show full overview
Beyond customer concentration, Cardinal Health also carries supplier concentration: its five largest suppliers accounted for 37% of fiscal 2025 revenue, with the single largest supplier alone contributing about 9%. Layered on top of commercial concentration is a multi-year regulatory commitment - the company's opioid-related settlement (the NOSA) requires an independent monitor to oversee its controlled-substance anti-diversion program through 2027 and funding of a third-party data-aggregation clearinghouse through 2032, meaning a chunk of compliance cost and oversight is locked in for years regardless of near-term business performance.
See also: Healthcare · Medical Distribution
From Cardinal Health, Inc.'s most recent 10-K filing, extracted October 11, 2026.
Recent developments
updated 2026-10-13Recent Developments — Cardinal Health, Inc.
Latest news
- NEWS Cardinal Health, McKesson Double Down on CVS Deals Through 2032 — benzinga Oct 1, 2026 positive
- NEWS Cardinal Health Affirms FY2027 Adj EPS Of $12.40-$12.60 vs $12.04 Est — benzinga Oct 1, 2026 positive
- NEWS Cardinal Health Enters Into Binding LOI To Extend Existing Distribution Agreement With CVS Health Through June 30, 2032 — benzinga Oct 1, 2026 positive
- NEWS 9 Health Care Stocks Whale Activity In Today’s Session — benzinga Sep 18, 2026 neutral
- NEWS RBC Capital Initiates Coverage On Cardinal Health with Outperform Rating, Announces Price Target of $276 — benzinga Aug 19, 2026 positive
Generated 2026-10-13T11:42:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerCVS Health30%10-K Item 1A: 'Our largest customer, CVS Health, accounted for 30 percent of our fiscal 2025 revenue.'
- MEDIUMCustomerfive largest customers43%10-K Item 1A: 'our five largest customers, including CVS Health, accounted for 43 percent of our fiscal 2025 revenue'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02LOWBoard Chair Gregory B. Kenny retired from the Board effective March 20, 2026, with no disagreement cited; the Board appointed current director Patricia A. Hemingway Hall as Board Chair.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $238.08: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $226.18. Score 5.5/10, moderate confidence.
Take-profit target: $243.30 (+2.2% upside). Prior stop was $226.18. Stop-loss: $226.18.
Target reached (2.2% upside); Quality below floor (3.6 < 4.0).
Cardinal Health, Inc. trades at a P/E of 32.9 (forward 16.9). TrendMatrix value score: 6.1/10. Verdict: Sell.
24 analysts cover CAH with a consensus score of 4.2/5. Average price target: $270.
What does Cardinal Health, Inc. do?Cardinal Health distributes pharmaceuticals and medical products and operates specialty and at-Home Solutions...
Cardinal Health distributes pharmaceuticals and medical products and operates specialty and at-Home Solutions businesses through its Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, and Specialty segments. CVS Health, its largest customer, accounted for 30 percent of fiscal 2025 revenue.